Shows
Vorsicht, Kunde!Vorsicht, Kunde! – Ungeplante PreiserhöhungDer Verbraucherschutz-Podcast der c’t
In der sechsten Episode des c’t-Verbraucherschutz-Podcast „Vorsicht, Kunde!“ geht es um überraschende Preiserhöhungen während eines laufenden Vertrags. Ulrike Kuhlmann und Urs Mansmann aus der c’t-Redaktion und Rechtsanwalt Niklas Mühleis klären dazu folgende Fragen:
Welche Rechte habt ihr als Kunden bei einer außerplanmäßigen Preiserhöhung? Wie könnt ihr euch gegen solche Preiserhöhungen wehren? Und wie solltet ihr reagieren, wenn der Vertragspartner die zusätzlichen Gebühren einfach abbucht.
Etwaige Vertragsänderungen hat das Telekommunikationsgesetz klar umrissen. Da jede Preiserhöhung zugleich eine Vertragsänderung ist...
2024-05-2437 min
IM Journal ClubNetwork Meta-Analysis w/ Dr. Ulrich MansmannWe are proud to bring you our first methods primer! We will consider methods primers whenever we cover a study with a more an usual or slightly more complicated methods. Last week's network-meta-analysis on DVT prophylaxis with Dr. Tony Breu should certainly qualify!Meta-analysis (both the classical one and the network type) can provide a quantitative synthesis of controlled studies (e.g., randomized controlled trials).NETWORK meta-analysis can help with two additional things:Through indirect treatment comparison (or a combination of indirect and direct comparison) it can increase your...
2022-11-0418 min
IM Journal ClubModeling COVID-19 w/ Dr. Ulrich MansmannSince the onset of the COVID-19 pandemic, we have come a long way to understand the complex and changing dynamics of the severe acute respiratory syndrome caused by this virus (SARS-CoV-2).Mathematical modeling and quantitative analysis of empirical data played a pivotal role to answer the emerging questions as the pandemic unfolds and to better understand and control the pandemic. Three articles are presented that describe and critique the role of modeling during the pandemic.Speaker: Ulrich Mansmann, Ph.D. (LMU Munich, Germany)0:00 Intro2:12 Why model COVID-19?5:55...
2022-10-2742 minIM Journal ClubWelcomeDo you also find it hard to follow the medical literature?Newsletters with tables of contents are hard to get through after having written all your notes and maybe having done a chart dissection.Welcome to IM Journal Club!Our mission: to guide you through some of the most interesting internal medicine studies published in the last few weeks and months that you WOULD have liked to or SHOULD have heard aboutTarget groups: physicians and other clinicians in general internal or family medicine – hospital medicine and primary ca...
2022-10-2702 min
re:publica 19 - Science & TechnologyDr. Algorithmus – Das berechnete GesundheitsrisikoIm Gesundheitsbereich werden große Erwartungen an die Nutzung von Big Data, Algorithmen und Machine Learning gestellt. Ein Beispiel dafür sind Risikorechner, mit denen das persönliche Krankheitsrisiko bestimmt werden kann. Sie sollen Gesunden, Kranken und ÄrztInnen Orientierung geben und Entscheidungen erleichtern. Die Tools sind komplex, aber verlockend einfach zu bedienen. Zeit, sie zu hinterfragen.
Brigitte StrahwaldUlrich MansmannOnline sind zahllose Tools verfügbar, mit denen das individuelle Risiko für Herzinfarkt, Krebs oder sogar eine verkürzte Lebenserwartung mit wenigen Mausklicks berechnet werden kann. Aber lässt sich die eigene gesundheitliche Zukunft so einfach bestimmen? Für die Nu...
2019-05-0833 min
ISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013Penalization Theory and Practice for Cox ModelsISCB 2013
2019-04-1829 minISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013Biomarker-based phase III clinical trial: Real-world experiencesISCB 2013
2019-04-1823 minISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013Estimating effects of time-varying treatments: pitfalls and opportunitiesISCB 2013
2019-04-1830 minISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013Evaluating and addressing consistency of the evidence in a network metaanalysisISCB 2013
2019-04-1819 minISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013Recent developments in updating and extending risk prediction models, the European Randomized Study of Prostate Cancer Risk CalculatorISCB 2013
2019-04-1829 minISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013From model building to validation and back: a plea for robustnessISCB 2013
2019-04-1857 minISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013Using network meta-analysis for decision makingISCB 2013
2019-04-1822 minISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013Joint longitudinal survival models for prediction of prostate cancer recurrence following radiotherapyISCB 2013
2019-04-1823 minISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013Adaptive designs for confirmatory clinical trials with treatment selectionISCB 2013
2019-04-1819 minISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013Recent developments in updating and extending risk prediction models, the Prostate Cancer Prevention Trial Calculatorcontribution and discussion
2013-08-2947 minISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013Gene signatures as treatment modifiers in clinical trialISCB 2013
2013-08-2924 minISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013Biomarker-based phase II trial designsISCB 2013
2013-08-2922 minISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013Utility-Based Dose-Finding with Ordinal Toxicity and EfficacyISCB 2013
2013-08-2918 minISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013Causal search in high-dimensional settingsISCB 2013
2013-08-2925 minISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013Assessing mediation through multiple pathways using natural effect modelsISCB 2013
2013-08-2823 minISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013The meta-analytic approach to validation of surrogate endpointsISCB 2013
2013-08-2822 minISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013TBD (on meta-regression)ISCB 2013
2013-08-2819 minISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013Two folklores: ridge regression versus the lassoISCB 2013
2013-08-2728 minISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013Purposeful penalization of likelihood in small samplesISCB 2013
2013-08-2727 min